CA3122067A1 - Engineered flagellin-derived compositions and uses - Google Patents

Engineered flagellin-derived compositions and uses Download PDF

Info

Publication number
CA3122067A1
CA3122067A1 CA3122067A CA3122067A CA3122067A1 CA 3122067 A1 CA3122067 A1 CA 3122067A1 CA 3122067 A CA3122067 A CA 3122067A CA 3122067 A CA3122067 A CA 3122067A CA 3122067 A1 CA3122067 A1 CA 3122067A1
Authority
CA
Canada
Prior art keywords
amino acid
flagellin variant
flagellin
residue
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3122067A
Other languages
English (en)
French (fr)
Inventor
Vadim Mett
Andrei Gudkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genome Protection Inc
Original Assignee
Genome Protection Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genome Protection Inc filed Critical Genome Protection Inc
Publication of CA3122067A1 publication Critical patent/CA3122067A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3122067A 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses Pending CA3122067A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776507P 2018-12-07 2018-12-07
US62/776,507 2018-12-07
PCT/US2019/064954 WO2020118192A1 (en) 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses

Publications (1)

Publication Number Publication Date
CA3122067A1 true CA3122067A1 (en) 2020-06-11

Family

ID=70974397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3122067A Pending CA3122067A1 (en) 2018-12-07 2019-12-06 Engineered flagellin-derived compositions and uses

Country Status (10)

Country Link
US (1) US20220024991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890769A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022511881A (cg-RX-API-DMAC7.html)
KR (1) KR20210111770A (cg-RX-API-DMAC7.html)
CN (1) CN113382742A (cg-RX-API-DMAC7.html)
AU (1) AU2019392903A1 (cg-RX-API-DMAC7.html)
CA (1) CA3122067A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191610A1 (cg-RX-API-DMAC7.html)
IL (1) IL283757A (cg-RX-API-DMAC7.html)
WO (1) WO2020118192A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720967B1 (ko) * 2020-06-04 2024-10-23 가톨릭대학교 산학협력단 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물
CN119522108A (zh) * 2022-06-01 2025-02-25 弗莱格生物公司 Rna佐剂、其方法和用途
KR102896818B1 (ko) * 2022-10-19 2025-12-08 전남대학교 산학협력단 Tlr5 활성능을 가진 플라젤린 면역증강제 유도체의 진핵세포 발현시스템을 이용한 제조 및 응용
KR20240081501A (ko) * 2022-11-14 2024-06-10 전남대학교산학협력단 암의 치료용 면역증강 살모넬라 균주 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121734B1 (en) * 2007-02-09 2013-05-08 Industry Foundation of Chonam National University Modified flagellin improved toll-like receptor 5 stimulating activity
US9376495B2 (en) * 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
CA2903252C (en) * 2013-03-14 2023-01-17 Research Corporation Technologies, Inc. Ribotoxin molecules derived from sarcin and other related fungal ribotoxins
EP3174893B1 (en) * 2014-07-30 2020-05-06 Genome Protection, Inc. Flagellin compositions and uses

Also Published As

Publication number Publication date
US20220024991A1 (en) 2022-01-27
IL283757A (en) 2021-07-29
EA202191610A1 (ru) 2021-10-25
CN113382742A (zh) 2021-09-10
AU2019392903A1 (en) 2021-06-24
JP2022511881A (ja) 2022-02-01
EP3890769A4 (en) 2022-11-23
EP3890769A1 (en) 2021-10-13
KR20210111770A (ko) 2021-09-13
WO2020118192A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
US11034733B2 (en) Flagellin compositions and uses
US20220024991A1 (en) Engineered flagellin-derived compositions and uses
KR102631377B1 (ko) 조합 요법을 위한 환자의 선별
JP7740994B2 (ja) 抗cd19抗体薬物複合体とpi3k阻害剤又は二次薬剤を含む併用治療
WO2016014899A1 (en) Flagellin derivatives and uses
JP2025179057A (ja) 併用療法のための患者の選択
CA3167799C (en) Combined use of pertuzumab, trastuzumab, and anthracycline-based chemotherapy for neoadjuvant therapy of early-stage her2-positive breast cancer
HK1237803A1 (en) Flagellin compositions and uses
HK1237803B (en) Flagellin compositions and uses
HK40096805A (en) Selection of patients for combination therapy
HK40050163B (en) Selection of patients for combination therapy
HK40050163A (en) Selection of patients for combination therapy
Seifert The Inflammatory Response Initiated by the Spleen to Ischemic Stroke
LUNGCANCER INTERRELATION BETWEEN MOLECULAR MECHANISMS OF DRUG RESISTANCE AND CELLULAR STRESS RESPONSE